One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Erectile Dysfunction Drugs Market

[ 英語タイトル ] Erectile Dysfunction Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0082905
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Apricus Biosciences Inc.
- Bayer AG
- Eli Lilly and Company
- Ferring Pharmaceuticals
- GlaxoSmithKline plc.
- Metuchen Pharmaceuticals LLC
- Pfizer Inc.
- S.K. Chemicals Co. Ltd
- Teva Pharmaceutical Industries Ltd
- VIVUS Inc.

[Report Description]

The erectile dysfunction drugs market is expected to register a CAGR of nearly 8.00% during the forecast period.

The major factors leading to the growth of the erectile dysfunction (ED) drugs market include the rising adoption of a sedentary lifestyle along with the associated stress, rising geriatric population, and comorbidity between erectile dysfunction and heart diseases, and diabetes.

Sedentary lifestyle, alcoholism, and smoking greatly increase the risk of erectile dysfunction. Increasing adoption of these poor lifestyle choices will lead to the overall growth of the erectile dysfunction drugs market.

The rise in the number of ED cases can be correlated with the high growth of obesity, diabetes, and cardiovascular disorders. Hypertension is also another major illness linked to erectile dysfunction and as reported by CDC in 2018, the prevalence of hypertension has grown at a considerable rate, with approximately 65 million people suffering from the condition in the United States.

Key Market Trends

Retail Pharmacies is the Segment by Distribution Channel is expected to Dominate the Market

- The retail pharmacies are expected to dominate the market due to the easy availability of erectile dysfunction drugs at retail stores.
- As per the data published by the Consumer Healthcare Products Association, there are more than 750,000 retail establishments in the United States, both rural and urban consumers have access to treatments for various conditions, 24*7.
- Furthermore, according to the Journal of Sexual Medicine, 2020, ED is increasingly prevalent with age and particulary those men are affected at age 40.
- Thus, owing to the easy availability of the drug and rising cases of ED, the market is expected to witness high growth over the forecast period.

North America is Expected to Dominate the Market

- North America is expected to dominate the erectile dysfunction drugs market, owing to the rising geriatric population, increase in cases of ED and the presence of better healthcare infrastructure.
- According to the United States Census Bureau’s Statistics as of 2017, the total number of people 65 and older exceeds 50 million, and between 2020-2030 the number of elderly is projected to increase by almost 18 million.
- The rise in geriatric population is expected to increase the number of patients suffering from ED, as it is very common in men above age 40. The availability of various ED drugs through over the counter (OTC) and online channels is a key factor for dominance of these regions.
- The presence of online pharmacy stores is a blessing in disguise for several patients who are conscious about visiting a retail pharmacy store to purchase ED and other sexual wellness products.

Competitive Landscape

The market studied is a fragmented market owing to the presence of the various small and large market players. Some of the market players are Apricus Biosciences, Inc., Bayer AG, Eli Lilly and Company, Ferring Pharmaceuticals, GlaxoSmithKline plc., Metuchen Pharmaceuticals, LLC, Pfizer Inc., S.K. Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd., and VIVUS, Inc.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption of a Sedentary Lifestyle Along with the Associated Stress
4.2.2 Rising Geriatric Population
4.2.3 Comorbidity between Erectile Dysfunction and Heart Diseases, and Diabetes
4.3 Market Restraints
4.3.1 Reluctance of Patients to Seek Treatment
4.3.2 Poor Patient Adherence to ED Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 Viagra (sildenafil citrate)
5.1.2 Cialis (Tadalafil)
5.1.3 Levitra/Staxyn (vardenafil)
5.1.4 Stendra/Spedra (avanafil)
5.1.5 Zydena (udenafil)
5.1.6 Vitaros (Alprostadil Cream)
5.1.7 Other Products
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online Pharmacies
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Apricus Biosciences Inc.
6.1.2 Bayer AG
6.1.3 Eli Lilly and Company
6.1.4 Ferring Pharmaceuticals
6.1.5 GlaxoSmithKline plc.
6.1.6 Metuchen Pharmaceuticals LLC
6.1.7 Pfizer Inc.
6.1.8 S.K. Chemicals Co. Ltd
6.1.9 Teva Pharmaceutical Industries Ltd
6.1.10 VIVUS Inc.




Recommended reports